indication

For the treatment of gastrointestinal disorders associated with motility disturbances such as gastroesophageal reflux disease, non-ulcer dyspepsia and delayed gastric emptying.

mechanism of action

Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.

toxicity

The symptoms of overdose include drowsiness, confusion and extrapyramidal effects.

absorption

The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.

half life

3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.

drug interactions

Atropine: Anticholinergic agents like atropine may reduce the action of cinitapride.

Digoxin: Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.

Digoxin Immune Fab: Cinitapride can alter the absorption of digoxin as it simulates gastric emptying.

Methylscopolamine: Anticholinergic agents like methylscopolamine may reduce the action of cinitapride.

Scopolamine: Anticholinergic agents like scopolamine may reduce the action of cinitapride.